Hypertonic_JJ saline_JJ resuscitation_NN in_IN sepsis_NN Abstract_NP |_SYM The_DT review_NN by_IN Oliveira_NP and_CC colleagues_NNS on_IN the_DT subject_NN of_IN hypertonic_JJ saline_JJ resuscitation_NN in_IN sepsis_NN (_( included_VBN in_IN the_DT present_JJ issue_NN )_) suggests_VBZ possible_JJ benefits_NNS for_IN hypertonic_JJ saline_NN ._SENT There_EX is_VBZ a_DT firm_JJ experimental_JJ basis_NN for_IN the_DT actions_NNS of_IN hypertonic_JJ saline/hyperoncotic_JJ solutions_NNS in_IN hemorrhagic_JJ hypotension_NN ,_, which_WDT include_VBP expansion_NN of_IN blood_NN volume_NN ,_, improvement_NN in_IN cardiac_JJ index_NN ,_, favorable_JJ modulation_NN of_IN the_DT immune_JJ system_NN ,_, and_CC improvement_NN in_IN survival_NN ._SENT These_DT actions_NNS are_VBP presumed_VBN to_TO be_VB of_IN benefit_NN in_IN the_DT treatment_NN of_IN sepsis_NN or_CC septic_JJ shock_NN ._SENT However_RB ,_, there_EX are_VBP few_JJ experimental_JJ data_NNS regarding_VBG the_DT use_NN of_IN these_DT solutions_NNS ,_, and_CC clinical_JJ studies_NNS are_VBP descriptive_JJ ._SENT The_DT major_JJ impact_NN of_IN early_JJ administration_NN of_IN hypertonic_JJ solutions_NNS may_MD be_VB attenuation_NN of_IN tissue_NN injury_NN ,_, sepsis_NN ,_, and_CC septic_JJ shock_NN ._SENT Early_JJ and_CC aggressive_JJ fluid_JJ resuscitation_NN with_IN hypertonic_JJ solutions_NNS to_TO clinical_JJ end-points_NNS should_MD be_VB investigated_VBN in_IN patients_NNS with_IN systemic_JJ inflammatory_JJ response_NN syndrome_NN ,_, sepsis_NN ,_, and_CC septic_JJ shock_NN ._SENT hemorrhage_NN ,_, hyperoncotic_JJ ,_, immune_JJ function_NN ,_, septic_JJ shock_NN ,_, shock_NN ,_, The_DT present_JJ discussion_NN focuses_VBZ on_IN the_DT review_NN by_IN Oliveira_NP and_CC coworkers_NNS (_( presented_VBN in_IN this_DT issue_NN )_) ,_, and_CC on_IN the_DT use_NN of_IN hypertonic_JJ saline_JJ resuscitation_NN in_IN sepsis_NN ._SENT Early_JJ fluid_JJ resuscitation_NN of_IN patients_NNS with_IN systemic_JJ inflammatory_JJ response_NN syndrome_NN reduces_VBZ the_DT incidence_NN of_IN mortality_NN due_JJ to_TO septic_JJ shock_NN and_CC sepsis_NN ._SENT These_DT favorable_JJ results_NNS have_VBP led_VBN to_TO consideration_NN of_IN other_JJ fluid_JJ modalities_NNS ._SENT In_IN their_PP$ review_NN ,_, Oliveira_NP and_CC coworkers_NNS consider_VBP the_DT use_NN of_IN hypertonic_JJ saline_JJ solutions_NNS in_IN the_DT treatment_NN of_IN patients_NNS with_IN severe_JJ sepsis_NN ._SENT Hypertonic_JJ saline_NN has_VBZ been_VBN extensively_RB investigated_VBN in_IN animal_JJ models_NNS with_IN regard_NN to_TO its_PP$ efficacy_NN in_IN treating_VBG hemorrhagic_JJ hypotension_NN ._SENT Numerous_JJ clinical_JJ studies_NNS of_IN patients_NNS with_IN traumatic_JJ injuries_NNS have_VBP been_VBN initiated_VBN with_IN favorable_JJ ,_, but_CC not_RB definitive_JJ ,_, results_NNS ._SENT Limited_JJ animal_NN studies_NNS have_VBP been_VBN directed_VBN at_IN treatment_NN of_IN septic_JJ shock_NN using_VBG hypertonic_JJ solutions_NNS ,_, and_CC clinical_JJ studies_NNS have_VBP been_VBN exploratory_JJ at_IN best_JJS ._SENT Hannemann_NP and_CC coworkers_NNS studied_VBD 21_CD stable_JJ patients_NNS with_IN septic_JJ shock_NN ._SENT Patients_NNS were_VBD administered_VBN 2_CD --_: 4_CD ml/kg_NN hypertonic_JJ saline_NN in_IN hydroxyethyl_NN starch_NN ._SENT Following_VBG administration_NN there_EX was_VBD a_DT small_JJ effect_NN on_IN oxygenation_NN by_IN increasing_VBG cardiac_JJ output_NN and_CC oxygen_NN delivery_NN ._SENT There_EX was_VBD no_DT control_NN group_NN in_IN this_DT study_NN for_IN comparison_NN ._SENT An_DT abstract_NN reported_VBD by_IN Oliveira_NP an_DT colleagues_NNS described_VBD a_DT randomized_VBN study_NN of_IN 25_CD stable_JJ patients_NNS with_IN sepsis_NN ._SENT Administration_NN of_IN 250_CD ml_NN hypertonic_JJ saline_NN in_IN dextran_NN significantly_RB improved_VBN cardiac_JJ index_NN and_CC pulmonary_JJ artery_NN occlusion_NN pressure_NN as_IN compared_VBN with_IN administration_NN of_IN an_DT equivalent_JJ volume_NN of_IN normal_JJ saline_NN ._SENT Although_IN favorable_JJ ,_, those_DT studies_NNS of_IN responses_NNS to_TO hypertonic_JJ saline_JJ solutions_NNS in_IN stable_JJ patients_NNS with_IN sepsis_NN are_VBP only_RB descriptive_JJ ._SENT Furthermore_RB ,_, administration_NN of_IN hypertonic_JJ saline_JJ solutions_NNS during_IN the_DT early_JJ stages_NNS of_IN septic_JJ shock_NN when_WRB the_DT patient_NN is_VBZ not_RB yet_RB hyperdynamic_JJ has_VBZ not_RB been_VBN investigated_VBN ._SENT The_DT major_JJ benefit_NN of_IN hypertonic_JJ solutions_NNS is_VBZ the_DT rapid_JJ expansion_NN of_IN blood_NN volume_NN for_IN a_DT small_JJ volume_NN administered_VBN ._SENT This_DT advantage_NN is_VBZ sustained_VBN by_IN the_DT addition_NN of_IN colloids_NNS such_JJ as_IN dextran_NN ._SENT In_IN their_PP$ review_NN ,_, Oliveira_NP and_CC colleagues_NNS suggest_VBP that_IN the_DT major_JJ benefit_NN of_IN resuscitation_NN with_IN hypertonic_JJ solutions_NNS in_IN models_NNS of_IN septic_JJ shock_NN is_VBZ the_DT restitution_NN of_IN blood_NN volume_NN and_CC accompanying_JJ improvements_NNS in_IN cardiovascular_JJ and_CC hemodynamic_JJ function_NN ._SENT Hypertonic_JJ solutions_NNS have_VBP been_VBN demonstrated_VBN to_TO modulate_VB the_DT immune_JJ system_NN ._SENT As_IN pointed_VBN out_RP by_IN Oliveira_NP and_CC coworkers_NNS ,_, hypertonic_JJ saline_NN has_VBZ a_DT pronounced_JJ anti-inflammatory_JJ effect_NN that_WDT could_MD reduce_VB the_DT response_NN to_TO sepsis_NN and_CC attenuate_VB later_RBR multiple_JJ organ_NN failure_NN ._SENT Recently_RB ,_, Shi_NP and_CC coworkers_NNS found_VBD resuscitation_NN with_IN hypertonic_JJ saline_NN to_TO ameliorate_VB the_DT gut_NN and_CC lung_NN injury_NN seen_VBN following_NN use_NN of_IN Ringer_NP 's_POS lactate_NN ._SENT This_DT lack_NN of_IN injury_NN reduced_VBN bacterial_JJ translocation_NN ,_, and_CC would_MD presumably_RB reduce_VB the_DT incidence_NN of_IN sepsis_NN ._SENT Comparisons_NNS between_IN various_JJ resuscitation_NN solutions_NNS on_IN outcome_NN have_VBP been_VBN controversial_JJ ._SENT However_RB ,_, the_DT work_NN of_IN Rhee_NP and_CC colleagues_NNS in_IN comparing_VBG various_JJ solutions_NNS suggests_VBZ pronounced_JJ differences_NNS in_IN immune_JJ modulation_NN ._SENT The_DT question_NN that_WDT must_MD be_VB addressed_VBN is_VBZ whether_IN the_DT presently_RB available_JJ solutions_NNS are_VBP harmful_JJ in_IN conditions_NNS in_IN which_WDT immune_JJ function_NN is_VBZ challenged_VBN ,_, and_CC are_VBP thus_RB inappropriate_JJ to_TO use_VB ._SENT Rhee_NP and_CC coworkers_NNS showed_VBD that_IN hypertonic_JJ solutions_NNS ,_, especially_RB when_WRB combined_VBN with_IN dextran_NN ,_, are_VBP superior_JJ to_TO '_'' standard_NN of_IN care_NN '_POS solutions_NNS ._SENT This_DT leads_VBZ to_TO the_DT conclusion_NN that_WDT presently_RB used_VBD solutions_NNS may_MD be_VB harmful_JJ because_IN they_PP compromise_VB immune_JJ function_NN and_CC that_IN hypertonic_JJ solutions_NNS are_VBP of_IN benefit_NN because_IN they_PP do_VBP not_RB ._SENT In_IN their_PP$ review_NN ,_, Oliveira_NP and_CC coworkers_NNS discuss_VBP the_DT use_NN of_IN hypertonic_JJ solutions_NNS for_IN treatment_NN of_IN septic_JJ shock_NN ;_: however_RB ,_, they_PP do_VBP not_RB refer_VB to_TO the_DT possible_JJ prophylactic_JJ benefit_NN of_IN early_JJ use_NN of_IN these_DT solutions_NNS ._SENT The_DT etiology_NN of_IN sepsis_NN is_VBZ based_VBN on_IN a_DT sustained_JJ period_NN of_IN hypoperfusion_NN of_IN vital_JJ organs_NNS ._SENT Rivers_NNS and_CC colleagues_NNS demonstrated_VBD early_JJ resuscitation_NN to_TO improve_VB survival_NN ._SENT The_DT use_NN of_IN hypertonic_JJ solutions_NNS as_IN the_DT initial_JJ fluid_JJ therapy_NN ,_, irrespective_RB of_IN the_DT cause_NN of_IN hypotension_NN or_CC cardiac_JJ insufficiency_NN ,_, may_MD be_VB of_IN benefit_NN in_IN blocking_VBG the_DT cascade_NN that_WDT leads_VBZ to_TO septic_JJ shock_NN ._SENT In_IN a_DT study_NN of_IN trauma_NN patients_NNS initially_RB resuscitated_VBN with_IN hypertonic_JJ saline_JJ dextran_NN ,_, no_DT cases_NNS of_IN sepsis_NN occurred_VBN in_IN the_DT hypertonic_JJ saline_JJ group_NN as_IN compared_VBN with_IN an_DT incidence_NN of_IN 2_CD %_NN in_IN the_DT standard_NN of_IN care_NN group_NN ._SENT Although_IN interesting_JJ ,_, this_DT difference_NN was_VBD not_RB significant_JJ ._SENT The_DT favorable_JJ preservation_NN of_IN tissues_NNS and_CC immune_JJ function_NN that_WDT occurs_VBZ following_VBG early_JJ resuscitation_NN of_IN the_DT hypotensive_JJ patient_NN with_IN hypertonic_JJ solutions_NNS bodes_VBZ well_RB for_IN a_DT favorable_JJ outcome_NN in_IN the_DT treatment_NN of_IN sepsis_NN ._SENT Oliveira_NP and_CC colleagues_NNS point_VBP out_RP the_DT probable_JJ advantages_NNS of_IN using_VBG hypertonic_JJ solutions_NNS in_IN patients_NNS with_IN sepsis_NN ._SENT There_EX is_VBZ a_DT rapid_JJ and_CC sustained_JJ expansion_NN of_IN plasma_NN volume_NN ,_, leading_VBG to_TO improvement_NN in_IN cardiovascular_JJ function_NN ,_, rectification_NN of_IN microcirculatory_JJ blood_NN flow_NN ,_, and_CC favorable_JJ modulation_NN of_IN immune_JJ function_NN ._SENT All_DT of_IN these_DT factors_NNS may_MD contribute_VB to_TO improved_VBN outcomes_NNS in_IN patients_NNS with_IN sepsis_NN and_CC septic_JJ shock_NN ._SENT Beyond_IN the_DT scope_NN of_IN the_DT present_JJ commentary_NN is_VBZ the_DT possibility_NN that_IN early_JJ resuscitation_NN with_IN hypertonic_JJ solutions_NNS could_MD contribute_VB to_TO a_DT reduced_VBN incidence_NN of_IN sepsis_NN by_IN modulation_NN of_IN immune_JJ responses_NNS and_CC reduced_VBN tissue_NN injury_NN ._SENT These_DT improvements_NNS following_VBG hypertonic_JJ saline_JJ resuscitation_NN would_MD have_VB a_DT greater_JJR impact_NN on_IN the_DT subsequent_JJ course_NN of_IN patients_NNS admitted_VBN to_TO the_DT intensive_JJ care_NN unit_NN ._SENT At_IN present_JJ ,_, although_IN the_DT experimental_JJ data_NNS are_VBP positive_JJ and_CC the_DT rationale_NN for_IN use_NN of_IN hypertonic_JJ solutions_NNS in_IN the_DT care_NN of_IN patients_NNS with_IN sepsis_NN or_CC septic_JJ shock_NN is_VBZ reasonable_JJ ,_, definitive_JJ clinical_JJ studies_NNS as_RB to_TO the_DT safety_NN and_CC efficacy_NN in_IN this_DT patient_JJ population_NN are_VBP still_RB required_VBN ._SENT CEW_NP is_VBZ a_DT faculty_NN member_NN of_IN the_DT University_NP of_IN California_NP at_IN Davis_NP ,_, which_WDT holds_VBZ the_DT US_NP patent_NN for_IN hypertonic_JJ saline/hyperoncotic_JJ solutions_NNS ._SENT He_PP holds_VBZ advisory_JJ positions_NNS in_IN companies_NNS developing_VBG these_DT solutions_NNS and_CC serves_VBZ as_IN a_DT consultant_NN to_TO other_JJ companies_NNS ._SENT 